A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of CSX-1004 Injection in Healthy Adults
Latest Information Update: 23 Aug 2024
At a glance
- Drugs CSX 1004 (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; First in man
- Sponsors Cessation Therapeutics
Most Recent Events
- 21 Aug 2024 Status changed from recruiting to completed.
- 19 Jun 2024 According to Cessation Therapeutics media release, the company announced the presentation of preliminary data from this trial as an oral presentation at the annual meeting of the College on Problems of Drug Dependence (CPDD) in Montreal on June 19 at 11:30 am ET.
- 24 Aug 2023 New trial record